Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion

Shalchi, Zaid; Mahroo, Omar A.; Bunce, Catey; Mitry, Danny

doi:10.1002/14651858.cd009510.pub3

Cited by 30 publications

(27 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over 93% would choose the treatment again. In addition to a huge number of studies, which have shown that IVIs with anti-VEGF agents defeat blindness [15][16][17], our results point out that patients ascertain their benefit from therapy by themselves.…”

Section: Discussionsupporting

confidence: 55%

Treatment contentment and preference of patients undergoing intravitreal anti-VEGF therapy

Kellner

Bedar

Weinitz

et al. 2021

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

The aim of this study is to investigate patients´ treatment preference between the pro re nata (PRN) and treat and extend (T&E) regimens and their feelings and contentment undergoing intravitreal injections (IVI) with anti-vascular endothelial growth factor (anti-VEGF) agents. Methods Six months after the switch of the treatment regimen from PRN to T&E, answers of a 16-item questionnaire of 105 patients under IVI therapy regarding age, sex and treatment preference (T&E or PRN regimen), as well as burden and anxiety resulting from therapy, were evaluated. Analysis of associations between answers of the questionnaire was executed using Pearson's Chi 2 test and Mann-Whitney U test. P values ≤ 0.05 were considered statistically significant. Results Nearly all patients (90.5%) felt well informed about disease and therapy. Comparing treatment regimen, 13.7% thought PRN was better and 23.3% felt T&E was better. The majority considered PRN and T&E to be equal (60.3%). No significant association between treatment regimen and age (p = 0.15), gender (p = 0.35) and duration of IVI therapy (p = 0.42) was seen. The examination results are associated with fear in the majority of patients (53.3%). Fear about the IVI was indicated by 47.6% of individuals and was significantly associated with pain during treatment (p = 0.0003), pain after treatment (p = 0.004) and fear about unfavourable examination results regarding disease activity (p = 7.94 × 10 −7 ). Conclusions Most patients are satisfied with the IVI therapy and the treatment regimen. Fear of the IVI and particularly of unfavourable examination results demonstrate the high treatment burden for patients undergoing anti-VEGF therapy. These aspects should be taken into account by healthcare professionals.

show abstract

Section: Discussionsupporting

confidence: 55%

Treatment contentment and preference of patients undergoing intravitreal anti-VEGF therapy

Kellner

Bedar

Weinitz

et al. 2021

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Other treatments such as fundus laser photocoagulation involve the risk of destroying the normal function of the retina (Shalchi et al. 2020 ; Mones et al. 2021 ).…”

Section: Introductionmentioning

confidence: 99%

“…In addition, multiple intraocular injections raise the risk of serious intraocular infection. Other treatments such as fundus laser photocoagulation involve the risk of destroying the normal function of the retina (Shalchi et al 2020;Mones et al 2021). Currently, all the available treatment options for DR may result in poor treatment compliance and disease prognosis (Fajnkuchen et al 2020).…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic study of Tangwang Mingmu granule for the management of diabetic retinopathy based on network pharmacology

Wang

Xue

Wang

et al. 2021

Pharmaceutical Biology

View full text Add to dashboard Cite

Context Tangwang Mingmu granule (TWMM), a traditional Chinese medicine, has been widely used in the treatment of diabetic retinopathy (DR), the most common microvascular complication in diabetes mellitus. Objective To establish a method to select target compounds from herbs for a pharmacokinetic study using network pharmacology, which could be applied in clinical settings. Materials and methods First, UPLC/Q Exactive Q-Orbitrap and GCMS 2010 were used to determine the non-volatile and volatile ingredients of TWMM. Based on the identified compounds, network pharmacology was used to screen the key compounds and targets of TWMM in the treatment of DR. Based on the compound-target-pathway network and identification of components emigrant into blood, the potential compound markers in vivo were chosen. Then, Sprague-Dawley (SD) rats were administrated of TWMM at a 9.6 g/kg dose to investigating pharmacokinetic parameters using the UPLC-QQQ-MS. Results Ninety and forty-five compounds were identified by UPLC-MS and GC-MS, respectively. Based on the network pharmacology, nine compounds with a degree value above 15 were screened and implied that these compounds are the most active in DR treatment. Moreover, criteria of degree value greater than 7 were applied, and PTGS2, NOS2, AKT1, ESR1, TNF, and MAPK14 were inferred as the core targets in treating DR. After identification of components absorbed into blood, luteolin and formononetin were selected and used to investigate the pharmacokinetic parameters of TWMM after its oral administration. Conclusions The reported strategy provides a method that combines ingredient profiling, network pharmacology, and pharmacokinetics to determine luteolin and formononetin as the pharmacokinetic markers of TWMM. This strategy provides a clinically relevant methodology that allows for the screening of pharmacokinetic markers in Chinese medicines.

show abstract

“…There is a general consensus regarding the efficacy and safety of anti-VEGF intravitreal injections in macular exudative and neovascular diseases ( Figure 1 ) [ 54 , 55 , 56 , 57 , 58 ]. Owing to their relatively simple management and good tolerance, bevacizumab, ranibizumab and aflibercept are often used as a first line strategy.…”

Section: Anti-vegf Moleculesmentioning

confidence: 99%

Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments

Arrigo

Bandello

2021

Pharmaceutics

View full text Add to dashboard Cite

The management of exudative retinal diseases underwent a revolution due to the introduction of intravitreal treatments. There are two main classes of intravitreal drugs, namely anti-vascular endothelial growth factors (anti-VEGF) and corticosteroids molecules. The clinical course and the outcome of retinal diseases radically changed thanks to the efficacy of these molecules in determining the regression of the exudation and the restoration of the macular profile. In this review, we described the molecular features of classic retinal drugs, highlighting the main therapeutic targets, and we provided an overview of new emerging molecules. We performed a systematic review of the current literature available in the MEDLINE library, focusing on current intravitreal molecules and on new emerging therapies. The anti-VEGF molecules include Bevacizumab, Pegaptanib, Ranibizumab, Aflibercept, Conbercept, Brolucizumab, Abicipar-pegol and Faricimab. The corticosteroids approach is mainly based on the employment of triamcinolone acetonide, dexamethasone and fluocinolone acetonide molecules. Many clinical trials and real-life reports demonstrated their efficacy in exudative retinal diseases, highlighting differences in terms of molecular targeting and pharmacologic profiles. Furthermore, several new molecules are currently under investigation. Intravitreal drugs focus their activity on a wide range of therapeutic targets and are safe and efficacy in managing retinal diseases.

show abstract

Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion

Abstract: Trusted evidence. Informed decisions. Better health.

Cited by 30 publications

References 106 publications

Treatment contentment and preference of patients undergoing intravitreal anti-VEGF therapy

Treatment contentment and preference of patients undergoing intravitreal anti-VEGF therapy

Pharmacokinetic study of Tangwang Mingmu granule for the management of diabetic retinopathy based on network pharmacology

Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments

Contact Info

Product

Resources

About